How big is the BCG vaccine Market | Global Forecast, Size & Trends 2025

How big is the BCG vaccine Market?

According to 6Wresearch internal database and industry insights, the BCG (Bacillus Calmette-Guérin) vaccine market was valued at approximately USD 58.2 million in 2024 and is projected to surpass a valuation of USD 81.7 million by 2031, growing at a CAGR of 4.9%.
This growth is driven by the ongoing prevalence of tuberculosis (TB) in developing countries, rising government immunization programs, and increased use of BCG vaccines in bladder cancer treatment. Enhanced awareness about infectious disease prevention is also supporting long-term market expansion.

Key Growth Factors in BCG Vaccine Market

High tuberculosis burden in Asia, Africa, and Latin America

Inclusion of BCG in national immunization schedules across multiple countries

Growing use of BCG vaccine as an immunotherapy for non-muscle-invasive bladder cancer

WHO and government-led TB eradication initiatives

Advancements in vaccine storage, distribution, and cold chain logistics

Support from international health organizations and funding agencies

BCG Vaccine Market Trends

The BCG vaccine market is anticipated to expand gradually due to extensive initiatives to eradicate tuberculosis and lower child mortality rates in high-risk areas. As part of their public health policies, many countries still require infants to obtain BCG vaccine. Extended applications are facilitated in bladder cancer, such as a medical vaccination in oncology by the use of BCG. Single-loaded versions are becoming more popular in an attempt to reduce waste and increase efficiency. Additionally, vaccine delivery innovation is being investigated such an intradinal device and microndele patch. In addition, the requirement of vaccines in high-departure areas is increasing as a result of monitoring and improving screening processes worldwide.

Emerging Developments in the BCG Vaccine Market

Recent developments in the BCG vaccine space include ongoing research into recombinant BCG strains that may offer broader immunity or enhanced therapeutic benefits. Biotech companies are examining BCG-based treatments for autoimmune diseases and other infectious diseases. Supply chain innovations are improving cold storage and transport to remote areas, ensuring consistent delivery in underserved markets. BCG vaccination ability to promote congenital immunity against respiratory infections is also being evaluated in several clinical trials. Pharmaceutical companies and public health organizations are collaborated to accelerate production and regulatory approval procedures. The clinical application and access to BCG vaccination is expanding globally as a result of these developments.

Major Companies in the BCG Vaccine Market

Serum Institute of India Pvt. Ltd.

InterVax Ltd.

Merck & Co., Inc.

Japan BCG Laboratory

Sanofi Pasteur

GreenSignal Bio Pharma Pvt. Ltd.

How big is the BCG vaccine Market : FAQs